The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRKR | -76.58% | -93.31% | -41.79% | -100% |
| S&P | +13.96% | +91.24% | +13.85% | +658% |
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.86M | -26.3% |
| Market Cap | $17.31M | -64.3% |
| Market Cap / Employee | $3.46M | 0.0% |
| Employees | 5 | -37.5% |
| Net Income | -$4.02M | -83.1% |
| EBITDA | -$4.26M | -84.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.81M | 51.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.48% | -49.2% |
| Return On Invested Capital | -81.54% | -1.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.88M | 47.3% |
| Operating Free Cash Flow | -$1.88M | 47.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.59 | 3.72 | 0.71 | 1.18 | -71.12% |
| Price to Sales | 4.66 | 4.29 | 2.40 | 3.96 | -69.50% |
| Price to Tangible Book Value | 2.59 | 3.72 | 0.71 | 1.18 | -71.12% |
| Enterprise Value to EBITDA | -6.74 | -2.36 | 0.01 | -2.24 | -87.28% |
| Return on Equity | -79.8% | -65.8% | -97.3% | -144.7% | 101.68% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
